4’-DMA-7,8-DHF (Eutropoflavin): A Nootropic for Neurogenesis and Mental Clarity

What Is 4’-DMA-7,8-DHF (Eutropoflavin)?

4’-DMA-7,8-DHF, also known as Eutropoflavin, is a synthetic derivative of 7,8-Dihydroxyflavone (7,8-DHF) — a flavonoid compound recognized for its ability to activate the TrkB receptor, mimicking the effects of brain-derived neurotrophic factor (BDNF). This receptor plays a crucial role in neurogenesis, synaptic plasticity, and overall cognitive function.

The addition of a dimethylamino group at the 4′ position enhances the compound’s potency, duration of action, and neuroprotective properties, making it a promising candidate in the field of cognitive enhancement and neuropsychiatric health.

💡 While no human trials exist to date, preclinical research supports its efficacy and potential.

Mechanism of Action: TrkB Receptor Agonism

The TrkB receptor is the high-affinity receptor for BDNF. Activation of TrkB stimulates downstream pathways including:

• PI3K/Akt: Promotes cell survival and anti-apoptotic signaling
• MAPK/ERK: Supports neuronal differentiation and synaptic plasticity
• PLC-γ: Involved in intracellular calcium signaling and memory consolidation

7,8-DHF and Eutropoflavin act as small-molecule mimetics of BDNF, binding directly to TrkB and initiating these signaling cascades independently of the endogenous neurotrophin.

“7,8-DHF is a novel TrkB agonist… [and] strongly provokes neurogenesis and displays robust antidepressant effects in a TrkB-dependent manner.” — Liu et al., 2010

Comparison: 7,8-DHF vs. 4’-DMA-7,8-DHF

While 7,8-DHF is already established as a TrkB agonist, Eutropoflavin (4’-DMA-7,8-DHF) takes this a step further:

• Greater TrkB activation
• Longer-lasting effects
• Improved oral bioavailability
• Stronger neuroprotective and antidepressant-like outcomes in preclinical models

According to Liu et al. (2010), Eutropoflavin “reveals more robust and longer TrkB activation” and exhibits more potent anti-apoptotic activity compared to its parent compound.

Preclinical Research and Benefits

1. Neuroprotection and Dopaminergic Neurons

• In a Parkinson’s disease rodent model, 7,8-DHF protected dopaminergic neurons, reduced motor deficits, and activated TrkB signaling cascades, including reductions in tau phosphorylation and α-synuclein aggregation.

2. Sleep Modulation and Depression Link

• Feng et al. (2015) found that 7,8-DHF significantly reduced non-REM sleep and suppressed orexin A levels in mice, suggesting a role in mood regulation through sleep architecture modulation.

3. Antidepressant-like Activity

• Chronic administration of 7,8-DHF and its methylated metabolites significantly reduced immobility in the forced swim and tail suspension tests—behavioral indicators of antidepressant effects.
• The O-methylated metabolites, such as those similar in structure to Eutropoflavin, also activated TrkB in vivo and contributed to these effects.

“Blocking methylation using COMT inhibitors diminished TrkB activation, supporting the contribution of methylated metabolites to TrkB activity in the brain.” — Liu et al., 2013

Neurogenesis and Cognitive Enhancement

Dentate Gyrus Neurogenesis

• Eutropoflavin promotes neurogenesis in the hippocampal dentate gyrus, an area critical for memory formation.
• This effect is consistent with the BDNF hypothesis of depression, which posits that increasing neuroplasticity and neuronal growth leads to improved mood and cognition.

Mental Clarity and Cognitive Support

While direct studies on Eutropoflavin and cognitive enhancement in humans are lacking, its activation of pathways tied to learning, memory, and neuroplasticity suggests a strong theoretical basis for supporting:

• Memory consolidation
• Executive function
• Stress resilience

Pharmacokinetics and Safety Notes

Eutropoflavin and related compounds:

• Are orally bioavailable
• Cross the blood-brain barrier
• Undergo O-methylation, a process that enhances brain activity through formation of active metabolites

Toxicity data is currently limited to preclinical models, and no formal safety studies in humans have been published.

Conclusion

4’-DMA-7,8-DHF (Eutropoflavin) shows great promise as a nootropic compound, targeting the TrkB-BDNF pathway to promote neurogenesis, mental clarity, and resilience against neurodegenerative and mood disorders.

While current evidence is limited to animal studies and in vitro models, the mechanistic backing and consistent neurotrophic activity across multiple studies highlight it as a compound worth watching in future research.

References

• Liu, X., Chan, C. B., Jang, S. W., Pradoldej, S., Huang, J., He, K., Phun, L. H., France, S., Xiao, G., Jia, Y., Luo, H. R., & Ye, K. (2010). A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. Journal of Medicinal Chemistry, 53(23), 8274–8286. https://doi.org/10.1021/jm101206p
• Liu, X., Qi, Q., Xiao, G., Li, J., Luo, H. R., & Ye, K. (2013). O-methylated metabolite of 7,8-dihydroxyflavone activates TrkB receptor and displays antidepressant activity. Pharmacology, 91(3–4), 185–200. https://doi.org/10.1159/000346920
• Yang, S., & Zhu, G. (2022). 7,8-Dihydroxyflavone and neuropsychiatric disorders: A translational perspective from the mechanism to drug development. Current Neuropharmacology, 20(8), 1479–1497. https://doi.org/10.2174/1570159X19666210915122820
• Nie, S., Ma, K., Sun, M., Lee, M., Tan, Y., Chen, G., Zhang, Z., Zhang, Z., & Cao, X. (2019). 7,8-Dihydroxyflavone protects nigrostriatal dopaminergic neurons from rotenone-induced neurotoxicity in rodents. Parkinson’s Disease, 2019, Article ID 9193534. https://doi.org/10.1155/2019/9193534
• Feng, P., Akladious, A. A., Hu, Y., Raslan, Y., Feng, J., & Smith, P. J. (2015). 7,8-Dihydroxyflavone reduces sleep during dark phase and suppresses orexin A but not orexin B in mice. Journal of Psychiatric Research, 69, 110–119. https://doi.org/10.1016/j.jpsychires.2015.08.002